- Home
- EM vs NTHI Comparison
EM vs NTHI Comparison
Compare EM & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EM | NTHI |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.1M | 243.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | EM | NTHI |
|---|---|---|
| Price | $1.11 | $7.65 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.25 | N/A |
| AVG Volume (30 Days) | ★ 51.5K | 26.8K |
| Earning Date | 04-27-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.30 | N/A |
| Revenue Next Year | $5.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $3.20 |
| 52 Week High | $1.46 | $16.00 |
Technical Indicators
Market Signals| Indicator | EM | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 35.82 | 39.45 |
| Support Level | $1.10 | $5.25 |
| Resistance Level | $1.18 | $10.52 |
| Average True Range (ATR) | 0.01 | 0.74 |
| MACD | -0.00 | -0.20 |
| Stochastic Oscillator | 0.00 | 26.03 |
Price Performance
Historical ComparisonAbout EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).